IP Library Granted Patent US 7,276,364
Granted Patent B1
US 7,276,364 · App. 09/717,473 · Granted Oct 2, 2007

Nucleic acids encoding endotheliases, endotheliases and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,276,364
App. No.
09/717,473
Granted
Oct 2, 2007
Kind
B1
Abstract

Provided herein are endotheliases and portions, particularly, the protease domains, and nucleic acids that encode the endotheliases. The endotheliases are transmembrane proteases expressed in endothelial cells. The nucleic acids and encoded proteins and protease domain portions thereof are used in a variety of prognostic, diagnostic, therapeutic and screening methods, including methods for screening for compounds that modulate angiogenesis.

Claims (63)

1. A substantially purified protein, consisting of a protease domain of an endotheliase protein that has catalytic activity, wherein:

the protease domain of the endotheliase is selected from the group consisting of:

a) a polypeptide consisting of the sequence of amino acid residues set forth as amino acids 320-562 of SEQ ID No. 4;

b) a polypeptide consisting of the sequence of amino acid residues set forth as amino acids 320-688 of SEQ ID No. 6; and

c) a protease domain of an endotheliase protein consisting of a sequence of amino acid residues that has at least 95% sequence identity to the sequence of amino acids set forth as amino acid residues 320-562 in SEQ IN No. 4 or amino acid residues set forth as amino acid residues 320-688 of SEQ ID No.6.

2. An isolated substantially purified endotheliase 1 protease domain, consisting of the sequence of amino acid residues as set forth in SEQ ID No. 2 or the sequence of amino acid residues set forth as residues 190-422 of SEQ ID No. 27, wherein the isolated purified endotheliase 1 protease domain has protease activity.

3. A substantially purified protein, comprising an endotheliase protein, wherein the endotheliase protein is an endotheliase 2 that comprises the sequence of amino acid residues set forth in SEQ ID No. 4 or 6.

4. The protein of claim 1 that is an endotheliase 2-L.

5. The protein of claim 1 that is an endotheliase 2-S.

6. A substantially purified endotheliase protein, comprising:

the sequence of amino acids set forth in SEQ ID No. 4 or 6; or

a sequence of amino acid residues that has at least 95% sequence identity to the sequence of amino acids set forth as SEQ ID No. 4 or 6, wherein the endotheliase protein is catalytically active.

7. A protein of claim 6 that specifically binds to an antibody that specifically binds to a protease domain of a protein comprising the sequence of amino acids set forth in SEQ ID No. 4 or 6.

8. A kit, comprising a protein of claim 1 and reagents for diagnostic, therapeutic or drug screening.

9. A kit, comprising a protein of claim 6 and reagents for diagnostic, therapeutic or drug screening.

10. A conjugate, comprising:

a) a protein of claim 1 , and

b) a targeting agent linked to the protein directly or via a linker;

wherein the conjugate has serine protease activity.

11. The conjugate of claim 10 , wherein the targeting agent permits

i) affinity isolation or purification of the conjugate;

ii) attachment of the conjugate to a surface;

iii) detection of the conjugate; or

iv) targeted delivery to a selected tissue or cell.

12. A conjugate, comprising an endotheliase of claim 6 and a targeting agent linked to the protein directly or via a linker, wherein the conjugate has serine protease activity.

13. A solid support, comprising two or more proteins of claim 1 immobilized thereon either directly or via a linker.

14. A solid support, comprising two or more proteins of claim 3 immobilized thereon either directly or via a linker.

15. The support of claim 13 , wherein the proteins comprise an array.

16. The support of claim 14 , wherein the proteins comprise an array.

17. A substantially purified endotheliase 2 that is encoded by SEQ ID No. 3 or SEQ ID No. 5.

18. A substantially purified endotheliase 2, comprising the sequence of amino acids set forth in SEQ ID No. 6 or consisting of amino acids 320-688 of SEQ ID No. 6.

19. A substantially purified endotheliase 2, comprising the sequence of amino acids set forth in SEQ ID No. 4 or consisting of amino acids 320-562 of SEQ ID No. 4.

20. A substantially purified endotheliase that has at least about 97% sequence identity with a protein that comprises the sequence of amino acids set forth in SEQ ID No. 4 or 6, wherein the substantially purified endotheliase comprises a catalytic triad.

21. A conjugate, comprising:

a) an endotheliase protein of claim 20 , and

b) a targeting agent linked to the protein directly or via a linker;

wherein the conjugate has serine protease activity.

22. An endotheliase protein, wherein the protease domain comprises the sequence of amino acids set forth in amino acids 321-562 of SEQ ID No. 4.

23. A substantially purified isolated polypeptide, consisting of an endotheliase protease domain that has at least 95% sequence identity with the sequence of amino acids set forth in SEQ ID No. 2 or amino acids 190-422 of SEQ ID No. 27 or a contiguous portion thereof that exhibits protease activity.

24. The conjugate of claim 21 , wherein the targeting agent permits

i) affinity isolation or purification of the conjugate;

ii) attachment of the conjugate to a surface;

iii) detection of the conjugate; or

iv) targeted delivery to a selected tissue or cell.

25. The conjugate of claim 12 , wherein the targeting agent permits

i) affinity isolation or purification of the conjugate;

ii) attachment of the conjugate to a surface;

iii) detection of the conjugate; or

iv) targeted delivery to a selected tissue or cell.

26. A conjugate, comprising:

a) a polypeptide of claim 23 , and

b) a targeting agent linked to the protein directly or via a linker;

wherein the conjugate has serine protease activity.

27. The conjugate of claim 26 , wherein the targeting agent permits

i) affinity isolation or purification of the conjugate;

ii) attachment of the conjugate to a surface;

iii) detection of the conjugate; or

iv) targeted delivery to a selected tissue or cell.

28. A kit, comprising a polypeptide of claim 23 and reagents for diagnostic, therapeutic or drug screening.

29. A solid support, comprising two or more polypeptides of claim 23 immobilized thereon either directly or via a linker.

30. A substantially purified protein, comprising the sequence of amino acid residues set forth in SEQ ID NO. 4 or 6.

31. A substantially purified protein of claim 30 , consisting of the sequence of amino acid residues set forth in SEQ ID NO. 4 or 6.

32. A substantially purified protein, comprising the sequence of amino acid residues set forth in SEQ ID NO. 4.

Assignments (9)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042389 FRAME: 505. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Feb 14, 2018
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 046088/0882 →
RELEASE OF SECURITY INTEREST Recorded Jul 5, 2017
From: BARCLAYS BANK PLC
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 043089/0288 →
CHANGE OF NAME Recorded May 3, 2017
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 042389/0505 →
SECURITY AGREEMENT Recorded Jul 27, 2015
From: DENDREON PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036190/0503 →
CHANGE OF NAME Recorded Jul 20, 2015
From: DRONE ACQUISITION SUB INC.
To: DENDREON PHARMACEUTICALS, INC.
Reel/Frame 036136/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2015
From: DENDREON CORPORATION, AND ITS WHOLLY OWNED SUBSIDIARIES, DENDREON HOLDINGS, LLC, DENDREON DISTRIBUTION, LLC, AND DENDREON MANUFACTORING, LLC
To: DRONE ACQUISITION SUB INC.
Reel/Frame 036126/0259 →
CHANGE OF NAME Recorded May 24, 2007
From: DENDREON CORPORATION
To: DENDREON CORPORATION
Reel/Frame 019349/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2003
From: DENDREON SAN DIEGO LLC
To: DENDREON CORPORATION
Reel/Frame 014702/0949 →
CHANGE OF NAME Recorded Oct 6, 2003
From: CORVAS INTERNATIONAL, INC.
To: DENDREON SAN DIEGO LLC
Reel/Frame 014570/0482 →